ST. HELIER, Jersey (AP) — ST. HELIER, Jersey (AP) — NovoCure Ltd. (NVCR) on Thursday reported a loss of $37.3 million in its third quarter.
The St. Helier, Jersey-based company said it had a loss of 33 cents per share.
The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share.
The oncology drug developer posted revenue of $167.2 million in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $158.1 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVCR at https://www.zacks.com/ap/NVCR
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)